Mallia Therapeutics Header

Based on 20 years of research on CD83

Developing novel therapies for people suffering from hair loss

Inducing new hair follicles & mediating hair regrowth

Mallia Therapeutics is a biopharmaceutical company developing soluble CD83 (sCD83) for the treatment of hair loss

sCD83 stimulates the formation of new hair follicles and thus inducing new hair growth, therefore this novel topical treatment is expected to revolutionize the treatment options for people suffering from hair loss. On top of the potential to re-grow hair, sCD83 is expected to exhibit a superior safety profile. As a human glycoprotein, that does not penetrate through the skin, sCD83 has no systemic availability and thus expected to have no systemic toxicity.

Although hair loss is not a life-threatening disorder, it can strikingly affect patient’s quality of life and is associated with higher prevalence of anxiety, depression and even suicide.

Clear medical need for an effective but safe treatment of patients suffering from hair loss

Worldwide leading experts in the field of CD83, with more than 60 publications and 20 years of experience in the field

Efficacy in a series of relevant preclinical models for androgenetic alopecia as well alopecia areata

sCD83 Stimulates The Formation Of New Hair Follicles And Thus Inducing New Hair Growth

Hair Growth Modulation

Non-systemic application of a human protein resulting in a low risk of failure due to safety reasons

sCD83 induces an anti-inflammatory micro-milieu

sCD83 directly binds to follicular stem cells and induces the formation of new hair follicles